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Candida albicans, a dimorphic fungus composed of yeast and mycelial forms, is the most common human fungal
pathogen. Th1 cytokines such as interleukin-2 (IL-2), gamma interferon (IFN-), and tumor necrosis factor alpha
(TNF-), which are induced by macrophage IL-12, are critical to resistance against systemic candidiasis, while Th2
cytokines such as IL-4 and IL-5 are less critical. Farnesol is a quorum-sensing molecule produced by C. albicans that
controls the formation of mycelia but is also a virulence factor. To determine whether farnesol enhances the
virulence of C. albicans by modulating the production of Th1 and Th2 cytokines, mice were pretreated with farnesol
prior to intravenous infection with a sublethal dose of farnesol-producing C. albicans. Production of IL-2, IL-4, IL-5,
TNF-, IFN-, and IL-12 was evaluated by bead-array flow cytometry and enzyme-linked immunosorbent assay.
Mice exhibited an elevation in serum TNF- levels at 48 h and an elevation in IFN- and IL-12 levels at 6 to 12 h
after infection with C. albicans. Pretreatment with farnesol significantly reduced the elevation of both IFN- and
IL-12 but not TNF-. In contrast, mice pretreated with farnesol exhibited an unexpected elevation in IL-5 levels. To
determine whether farnesol has a direct effect on macrophage production of IL-12, peritoneal macrophages were
pretreated with farnesol prior to stimulation with IFN- plus lipopolysaccharide (LPS). Farnesol inhibited pro-
duction of both IL-12 p40 and p70 from IFN-/LPS-stimulated macrophages. Therefore, the role of farnesol in
systemic candidiasis is likely due to its ability to inhibit the critical Th1 cytokines IFN- and IL-12 and perhaps to
enhance a Th2 cytokine, IL-5.
Candida albicans is a dimorphic commensal fungus and a
medically important opportunistic pathogen, particularly in
immunocompromised individuals (37). Previous work showed
that yeast-mycelium dimorphism in C. albicans is regulated in
part by secretion of a lipophilic molecule identified as farnesol
(15). Farnesol prevents mycelial development in a quorum-
sensing or cell density-dependent manner, and it was the first
quorum-sensing molecule (QSM) discovered in a eukaryotic
organism. This work was recently reviewed by Nickerson et al.
(33). However, all of the work on farnesol as a QSM has been
done in vitro, leaving open the question of what role farnesol
or farnesol analogs have in vivo. In this regard, Hornby et al.
(15) proposed two competing hypotheses. The first was that
the shift from yeast to mycelium was a critical step in patho-
genesis and that exogenous farnesol could block this transition,
thus acting in a therapeutic manner. The alternate hypothesis
was that the lipophilic farnesol excreted during infection would
interact with host cells in a manner that promoted virulence.
The latter idea was supported by our work on the pathogenicity
of C. albicans cells pretreated with subinhibitory concentra-
tions (0.5 to 1 M) of fluconazole (29). These cells secreted 10
times more farnesol than did untreated cells, and they were 4.2
to 8.5 times more lethal (P  0.001) than untreated cells in a
mouse model of intravenously disseminated candidiasis.
This indication that farnesol might be a virulence factor was
explored more fully in our recent work, which showed that
farnesol promoted virulence by C. albicans (30). This increased
virulence was observed when mice received farnesol either
intraperitoneally or orally in their drinking water. It was also
observed for a C. albicans mutant with a knockout of DPP3,
encoding a phosphatase that converts farnesyl pyrophosphate
to farnesol. This mutant (KWN2) produced 6 times less far-
nesol and was 4.2 times less pathogenic to mice than its parent.
The strain with DPP3 reconstituted (KWN4) regained both its
farnesol production levels and pathogenicity.
These data suggest that farnesol excretion should be in-
cluded among a list of virulence factors for C. albicans, but they
say nothing about what the mode of action of farnesol might
be. At that time we suggested four possibilities: farnesol might
(i) promote invasiveness by altering the membrane fluidity of
host cells; (ii) lyse red blood cells, making iron available for
fungal growth; (iii) protect C. albicans from phagocytes by
countering their oxidative burst (51); or (iv) interfere with
aspects of host defense necessary to survive fungal infection.
The present work shows that the last possibility is a correct one
but possibly not the only correct one. Farnesol interferes with
the normal progression of cytokine induction in mice infected
with C. albicans.
The pathophysiologies of disseminated candidiasis in mice
and humans are very similar. During early innate immune
responses against systemic candidiasis, phagocytosis and both
oxidative and nonoxidative mechanisms (8) of monocytes and
macrophages (4) destroy both yeast and hyphae of C. albicans.
During the adaptive immune response, cell-mediated immu-
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nity, with macrophages, T cells, and their cytokines, is required
for complete resistance against disseminated candidiasis. In
this regard, macrophage interleukin-12 (IL-12) induces the
differentiation of CD4 T cells to a Th1 phenotype. The cyto-
kines produced by Th1 cells, gamma interferon (IFN-) and
tumor necrosis factor alpha (TNF-), signal an increase in the
anticandidal activities of macrophages and reinforce expres-
sion of IL-12 (2). Therefore, IL-12 is a critical macrophage
cytokine in immunity to systemic candidiasis.
On the other hand, IL-4 plays the pivotal role in develop-
ment of an another subset of CD4 T cells, Th2, which secrete
IL-4, IL-5, IL-10, and IL-13 (28, 45). These cytokines are
necessary for antibody responses but antagonize the develop-
ment and activity of Th1 cells. Therefore, cytokines from Th1
cells have been associated with resistance to C. albicans infec-
tion, while Th2 appears to increase susceptibility to infection.
This hypothesis is supported by a study which showed that
patients with chronic mucocutaneous candidiasis exhibit Th2
cytokine production during the immune response to C. albi-
cans (20). Furthermore, TNF-, released by both hematopoi-
etic and nonhematopoietic cells, has been shown to play a vital
role in host defense in systemic candidiasis (5). Therefore,
TNF-, IFN-, and IL-12 are associated with effective resis-
tance to C. albicans infection in mice. A comparative study of
C. glabrata and C. albicans revealed that delayed induction or
absence of these cytokines during early infection increases
susceptibility to C. albicans (5). Therefore, it is likely that if
innate macrophage and adaptive cell-mediated immune re-
sponses are compromised, then the containment of commensal
C. albicans at mucosal surfaces is impaired, leading to systemic
candidiasis (2, 39).
C. albicans may have a number of virulence factors that
delay T-cell and macrophage cytokine expression. We have
shown that C. albicans produces farnesol, which acts as a QSM
to control mycelial development in vitro. In this study, we
examined a possible role of farnesol in modulating resistance
against systemic candidiasis, as well as in modulating T-cell and
macrophage cytokine expression. The results show that farne-
sol increases the susceptibility of mice to systemic candidiasis.
In addition, farnesol decreases expression of the Th1 cytokine
IFN- and the Th1-inducing cytokine IL-12 and increases ex-
pression of the Th2 cytokine IL-5.
MATERIALS AND METHODS
Preparation of farnesol. Commercially available E,E-farnesol (Sigma, St.
Louis, MO) was used in all experiments. Tween 80 (0.5%) in sterile nonpyro-
genic normal saline was used to dilute the farnesol to the required concentra-
tions. The solubility of farnesol in water is 1.2 mM; therefore, 0.5% Tween 80 was
used to increase the concentrations at which farnesol could be resuspended.
Farnesol in 0.5% Tween 80 or Tween 80 alone (control) was delivered by
intraperitoneal (i.p.) injection immediately before inoculation.
C. albicans and animal inoculation. Stock cultures of C. albicans A72 cells
were kept at 4°C and passaged once a month to maintain viability. Before each
experiment, C. albicans A72 cells were grown for 24 h in 50 ml of modified
glucose salts biotin medium (15) at 30°C with aeration. Cells were harvested by
centrifugation at 4,750  g for 10 min. Cells were washed three times with 50 ml
of sterile nonpyrogenic saline, counted with a hemacytometer, and resuspended
in saline to the required concentrations. Mice were inoculated intravenously
(i.v.) in the lateral tail vein. For those mice receiving both C. albicans (i.v.) and
farnesol/Tween 80 or Tween 80 alone, i.p. treatment occurred within 5 min of the
i.v. inoculation.
Mice. Female CF-1 mice (9 to 11 weeks old, 20 to 25 g) (Charles River
Laboratories, Wilmington, MA) were used for all experiments. Mice were
housed at five animals per cage and cared for according to approved protocols of
the Institutional Animal Care and Use Committee of the University of Nebraska.
The institutional standards are in accordance with all federal, state, and univer-
sity rules and regulations. Forty-eight mice were inoculated with 1.3  106 C.
albicans cells. Of those, 24 animals were also given farnesol i.p. Other control
groups consisted of 24 animals given farnesol administered i.p. and 24 animals
given 0.1% Tween 80 (the solvent for the farnesol stock) administered i.p. These
control groups received no fungal challenge. Therefore, the experimental and
control groups were as follows: C. albicans infected and also given an i.p. injec-
tion of Tween 80, C albicans infected and also given an i.p. injection of farnesol
in Tween 80, uninfected with an i.p. injection of farnesol in Tween 80, and
uninfected with an i.p. injection of Tween 80. Three animals from each group
were sacrificed at 1, 3, 6, 12, 18, 24, and 48 h postinoculation (p.i.). Twelve
control animals, i.e., untreated and uninfected, were sacrificed, and the serum
was collected. The mean results for these 12 control animals are shown as time
zero values in Fig. 1 through 3. Sera separated from the blood collected from
individual mice were stored at 80°C until the day of analysis. The same exper-
iment was repeated to examine the IL-12 response by enzyme-linked immu-
nosorbent assay (ELISA) but did not include the 18-h p.i. groups.
Macrophages. Macrophages were harvested from the peritoneal cavity 3 days
after injection of 3% thioglycolate medium (Difco, Detroit, MI). Macrophages
were maintained in Dulbecco modified Eagle medium (Invitrogen, Carlsbad,
CA) containing 10% fetal bovine serum (FBS) (Invitrogen) and 0.05 mg/ml
gentamicin (Invitrogen) and incubated at 37°C with 5% CO2. Peritoneal macro-
phages were cultured overnight, nonadherent cells were removed, and adherent
cells were either left untreated or were pretreated with 100 M farnesol and then
were either left unstimulated or were stimulated with 10 ng/ml recombinant
mouse IFN- (BD Pharmingen, San Diego, CA) plus 500 ng/ml Escherichia coli
O111:B4 lipopolysaccharide (LPS) (Invivogen, San Diego, CA). After 24 h,
supernatants were collected for IL-12 ELISAs.
Cytokine assays. (i) Bead array. Murine serum was collected from sacrificed
mice at various time points following infection with C. albicans with and without
farnesol pretreatment. The BD Cytometric Bead Array (CBA), the mouse Th1/
Th2 cytokine kit (catalog no. 551287) of BD Biosciences, San Diego, CA, was
used for the detection IL-2, IL-4, IL-5, TNF-, and IFN-, according to the
manufacturer’s specifications. Briefly, microbead populations with distinct fluo-
rescence intensities were coated with capture antibody specific for each cytokine.
The capture beads, phycoerythrin-conjugated detection antibodies, and recom-
binant standards or test samples were incubated at room temperature. The
samples are then washed with 1 ml of wash buffer and recovered by centrifuga-
tion (200  g for 5 min). After careful aspiration of the supernatant, the beads
were resuspended in 300 l of wash buffer, vortexed briefly, and analyzed with a
BD FACScan and BD CBA analysis software. Each assay had a sensitivity range
of 20 to 5,000 pg/ml.
(ii) ELISA. Ninety-six-well polyvinylchloride plates were coated with 2.0 g/ml
purified unconjugated anti-IL-12 p70 (clone 9A5) or anti-IL-12 p40 (clone
C15.6) monoclonal antibody (BD Pharmingen, San Diego, CA) in bicarbonate
buffer (pH 9.6) at 4°C overnight. After three washes with phosphate-buffered
saline (PBS)–0.05% Tween 20 (Sigma, St. Louis, MO), each plate was blocked
with PBS–10% FBS. For standard curves, serial dilutions of recombinant IL-12
p70 and IL-12 p40 (BD Pharmingen) were added to additional wells coated with
antibody. The plates were incubated at room temperature for 2 h. After four
washes with PBS-Tween 20, each plate was incubated with 2.5 g/ml biotinylated
anti-mouse IL-12 p40/p70 (clone C17.8) in PBS–10% FBS at room temperature
for 30 min. After five washes with PBS-Tween 20, the plates were incubated with
diluted (1:1,000) avidin-peroxidase (BD Pharmingen) at room temperature for
30 min. The plates were washed five times with PBS-Tween 20 and incubated
with 3,3,5,5-tetramethylbenzidine substrate/hydrogen peroxide solution (BD
Pharmingen). IL-12 p40 and p70 were measured by determining the optical
densities at 450 nm with an ELISA plate reader.
Statistics. The mixed procedure of the SAS system was used to analyze serum
cytokine expression patterns among all treatment groups at various time points.
Time trends of treatments were compared for significant differences by estimat-
ing and comparing means of each triplicate reading at various time points.
RESULTS
Farnesol reduces serum IFN- levels but increases serum
IL-5 levels during systemic candidiasis. IFN- and TNF- are
critical for immunity against systemic candidiasis. To deter-
mine whether farnesol modulates these cytokines during sys-
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temic candidiasis, the following experimental design was em-
ployed. Sera from 12 control mice were compared with a 1- to
48-h time sequence for four categories of three test mice each:
C. albicans infected and also given an i.p. injection of Tween
80, C. albicans infected and also given an i.p. injection of
farnesol in Tween 80, uninfected with an i.p. injection of far-
nesol in Tween 80, and uninfected with an i.p. injection of
Tween 80. Serum TNF-, IFN-, IL-5, and IL-12 concentra-
tions are shown in Fig. 1 through 4, respectively. For conve-
nience, the control sera (uninfected and untreated) are shown
at time zero. C. albicans infection significantly elevated TNF-
levels at 48 h p.i. (P  0.01), but farnesol alone did not stim-
ulate TNF- (Fig. 1) nor did it modulate TNF- production
during systemic candidiasis. Similarly, the serum IL-2 and IL-4
levels were present and detectable but not affected by C. albi-
cans infection or by farnesol administration either by itself or
in combination with C. albicans infection (data not shown).
However, C. albicans infection significantly increased IFN-
levels after 12 and 18 h (P, 0.03 and 0.01, respectively), and,
in contrast to its effect on TNF-, farnesol significantly de-
creased IFN- levels (Fig. 2) following C. albicans infection at
12 h (P  0.04).
Unlike Th1 cytokines, Th2 cytokines may antagonize effec-
tive immunity against systemic candidiasis. C. albicans infec-
tion alone did not increase serum IL-5 levels compared to
control mice. However, farnesol significantly elevated serum
IL-5 levels in C. albicans-infected mice at 3 and 6 h p.i. (P,
0.05 and 0.0001, respectively). In addition, farnesol itself
elevated IL-5 levels at 3, 6, and 12 h p.i. (P, 0.03, 0.0001, and
0.0001, respectively). As another control, the Tween 80 used
to dissolve farnesol did not significantly affect serum IL-5 levels
(Fig. 3).
Farnesol reduces serum IL-12 levels during systemic candi-
diasis. IL-12 is the determining macrophage cytokine that
stimulates both development of the Th1 subset and IFN-
production from CD4 T cells. Therefore, we examined serum
IL-12 levels in untreated or farnesol-treated mice infected with
C. albicans. Significantly different levels of IL-12 were observed
only at 12 h after C. albicans infection. At this time, farnesol
pretreatment significantly reduced the levels of serum IL-12
(P  0.04) in mice infected with C. albicans (Fig. 4).
Farnesol reduces in vitro macrophage production of IL-12
p70 and p40 expressed in response to IFN- plus LPS. The
data so far indicate that farnesol suppresses IFN- production
FIG. 2. Concentrations of IFN- in mouse sera at 1 to 48 h p.i.
Experimental groups are represented as described in the legend to Fig.
1. Data are means 	 standard deviations for 3 mice except where “a”
indicates 12 mice per group; “b” indicates means that are significantly
different from control values.
FIG. 1. Concentrations of TNF- in mouse sera at 1 to 48 h p.i.
Values at time zero are mean values for control sera from 12 mice,
open bars represent mean values for mice administered i.v. C. albicans
and i.p. Tween 80, closed bars represent mean values for mice admin-
istered i.v. C. albicans and i.p. farnesol in Tween 80, vertical-lined bars
represent mean values for mice administered i.p. farnesol in Tween 80,
and horizontal-lined bars represent mice administered i.p. Tween 80.
Data are means 	 standard deviations for 3 mice except where “a”
indicates 12 mice per group; “b” indicates means that are significantly
different from control values.
FIG. 3. Expression of IL-5 in mouse sera at 1 to 48 h p.i. Experi-
mental groups are represented as described in the legend to Fig. 1.
Data are means 	 standard deviations for 3 mice except where “a”
indicates 12 mice per group; “b” indicates means that are significantly
different from control values.
FIG. 4. Serum IL-12 levels at 12 h p.i. Treatments were C. albicans
(CA)/Tween 80 (Tw80), C. albicans plus farnesol (CA/F), farnesol (F),
and Tween 80 (Tw80) only. Data are means 	 standard deviations for
three mice. “a” indicates means that are significantly lower than those
for the C. albicans only and Tween 80 only groups.
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in response to C. albicans infection through its impact on
macrophage IL-12 p70, a cytokine composed of p35 and p40
subunits. In addition, p40 can form homodimers that have
antagonistic and agonistic effects. However, IL-12 p70-induced
IFN- feeds back and reinforces IL-12 production from mac-
rophages, while p40 homodimers antagonize this effect (22).
Macrophages produce the maximum amount of IL-12 p70 in
response to IFN- plus LPS (49). Thus, to determine whether
farnesol directly suppresses IL-12 p70 production compared
with IL-12 p40, primary peritoneal macrophages were pre-
treated with 100 M farnesol prior to stimulation with IFN-
plus LPS. This concentration of farnesol is considered relevant
for cells cultured in medium with 10% FBS (27). The data
indicate that the combination of IFN- and LPS potently stim-
ulates production of both IL-12 p40 and p70, 2,100- and 10-
fold, respectively (Table 1), while farnesol significantly sup-
presses production of IL-12 p40 (1,900-fold) and p70 (5-fold)
from IFN-/LPS-stimulated macrophages. Therefore, farnesol
suppression of immunity against systemic candidiasis likely oc-
curs through suppression of both IFN- production by T cells
and IL-12 production by macrophages.
DISCUSSION
The results of the present investigation show that farnesol, a
QSM of C. albicans, suppresses production of IFN- and IL-
12, but not TNF-, induced during the host response to C.
albicans. It is clear that TNF-, IFN-, and IL-12 are required
for resistance against systemic candidiasis. TNF- is required
for resistance to a number of pathogens, including Mycobacte-
rium tuberculosis (42), Listeria monocytogenes (19), and Neisse-
ria meningitidis (50). It is reported to be secreted by hemato-
poietic and nonhematopoietic cells during fungal infections
(21). Even though low levels of TNF- play a protective role by
inducing macrophages to produce microbicidal reactive inter-
mediates (11) and natural killer cells to produce IFN- (23),
high levels of TNF- are associated with organ failure and
septic shock in experimental lethal infections (24). Our find-
ings showing increased TNF- at 48 h p.i. in C. albicans-
infected mice agree with previous findings (18, 36, 39, 41).
TNF- is produced by a number of cell types following expo-
sure to C. albicans. This cytokine recruits inflammatory cells to
the site of infection, promotes growth and differentiation of T
cells, and activates endothelia (2). Therefore, increased TNF-
has been associated with Candida infection.
It was somewhat surprising that serum IL-2 and IL-4 were
present but not elevated at 48 h p.i. with C. albicans. However,
Romani et al. (40) similarly reported that C. albicans-infected
mice did not exhibit increased IL-2 and IL-4 levels at 2 days p.i.
but that they were elevated at 3 days p.i. Therefore, time after
C. albicans infection is likely critical to IL-2 and IL-4 expres-
sion. Interestingly, Scaringi et al. (43) reported that as early as
2 h after i.p. infection with C. albicans, and persisting for 5
days, IL-2 expression was detected in cells of the peritoneal
cavity, while TNF- and IL-5 expression was not detected. In
contrast, we clearly showed that after i.v. inoculation with C.
albicans, TNF- and IL-5 were detected in serum. This sug-
gests that the route of C. albicans inoculation may dictate the
T-cell cytokine phenotype.
In view of the robust expression of IFN- by 48 h p.i., and
since IL-4 expression is repressed by IFN-, it was not surpris-
ing that IL-4 expression was not induced further at 48 h p.i. It
was, however, somewhat surprising that we detected IL-5, an-
other Th2 cytokine, in response to farnesol. Since IL-4 is the
prototypical Th2 cytokine, IL-5 is secreted by activated Th2
following IL-4-induced differentiation (45, 46). While it is pos-
sible that farnesol directly stimulates expression of IL-5 from
CD4 T cells, the source of IL-5 is more likely to be mast cells
(35) or eosinophils (9) within the time frame that it was in-
duced in the present study. IL-5, together with IL-4 and IL-2,
contributes to activation and proliferation of B cells, while IL-5
by itself is also the terminal eosinophil differentiation factor
(53). Therefore, it is likely that farnesol-treated mice exhibit a
surge in eosinophil production. IL-5 is also a significant con-
tributing cytokine to the development of asthma (47), due to its
stimulation of eosinophil development (12). Others have re-
ported IL-5 expression during C. albicans infection (6), and it
is thought that C. albicans may play a role in the development
of certain allergies, including asthma (26, 34). Therefore, for
the first time, we show the mechanism by which C. albicans
induction of IL-5 could contribute to this crucial event during
the development of asthma (10, 17, 31, 38). It remains to be
determined whether the elevated levels of IL-5 produced in
response to farnesol play a significant role in inhibiting Th1
cytokine expression or in suppressing immunity to systemic
candidiasis.
In contrast to IL-2, we found that serum IFN- levels in-
creased in mice infected with C. albicans. Numerous studies
with a mouse model noted significant IFN- responses to C.
albicans infection (2, 40). However, in the present study, ex-
perimental groups administered farnesol and then challenged
with C. albicans exhibited a significant decrease in IFN- levels
compared with groups challenged with C. albicans but not
administered farnesol. Therefore, our finding of depressed el-
evation of IFN- levels in Candida-infected mice treated with
farnesol may explain why farnesol decreases resistance to sys-
temic C. albicans infection (30). It is not surprising that farne-
sol had no effect on IFN- levels after 12 h, since our recent
report (30) shows that administered farnesol is cleared from
the system after 12 h. Similar to IL-5, the source of IFN-
during C. albicans infection at 12 h is not likely to be CD4 T
cells of the adaptive immune response. It is more likely that
NK cells are a source of early IFN- secretion (1). However,
systemic candidiasis usually involves chronic infection of the
kidney. Spellburg et al. (44) reported that the basal concentra-
tion of IFN- is markedly higher in the kidneys than in spleen.
In addition, this group describes cells other than CD4 lym-
TABLE 1. Effects of farnesol on IL-12 expression in macrophages
Treatment
Mean IL-12 production 	 SD (pg/ml)
p40 p70
None 1.5 	 2 4.25 	 8
Farnesola 0.33 	 0.5 2 	 3.4
IFN- and LPSb 3,215 	 2,300 40.8 	 24
Farnesol/IFN- and LPSc 1.7 	 1.4 7.1 	 14
a Macrophages pretreated with 100 M farnesol.
b Macrophage IL-12 induced with 10 ng/ml IFN- and 500 ng/ml LPS.
c Macrophages pretreated with 100 M farnesol; IL-12 induced with 10 ng/ml
IFN- and 500 ng/ml LPS.
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phocytes in the kidney that produce IFN-. Therefore, C.
albicans may have a virulence factor, such as farnesol, that
suppresses IFN- production in the kidney. It is likely that the
significant source of serum IFN- is the kidney, and we pro-
pose that farnesol produced locally in the kidney by C. albicans
has a direct effect on IFN- production there.
While the mechanism by which farnesol induces IL-5 is un-
clear, the data presented here suggest that farnesol likely re-
duces expression of IFN- through a concomitant reduction in
IL-12 expression. Macrophage lineage cells produce IL-12 dur-
ing innate and adaptive immune responses. In addition to Th1
development, IL-12 stimulates proliferation of NK cells and
activation of CD8 cytolytic T cells (3, 7, 16, 48). IL-12 is a
heterodimer composed of p35 and p40 subunits (52). Deficien-
cies in IL-12 result in low IFN- production and impaired Th1
immune responses (13, 14, 25). However, a recent report shows
that IL-5 plays a significant role in repression of both IL-12 and
IFN- production (32). Thus, an understanding of the molec-
ular mechanisms by which farnesol decreases IL-12 p35 and
p40 expression will suggest strategies for therapeutically influ-
encing IL-12 production during systemic candidiasis.
Our next goal is to examine what C. albicans genetically
programmed to produce more farnesol would do to cytokine
expression in disseminated candidiasis. We recently found that
fluconazole-pretreated C. albicans is more virulent (29). We
hypothesize that a possible overproduction of farnesol during
antifungal therapy might cause greater virulence during dis-
seminated candidiasis.
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